Precigen公司宣布,其研发的Papzimeos (Zopapogene Imadenovec-Drba) 疗法已在美国获得孤儿药市场独占权资格。这一认定将为该药物在特定适应症领域提供为期七年的市场独占保护,有助于激励针对罕见疾病的创新疗法开发。
Precigen公司宣布,其研发的Papzimeos (Zopapogene Imadenovec-Drba) 疗法已在美国获得孤儿药市场独占权资格。这一认定将为该药物在特定适应症领域提供为期七年的市场独占保护,有助于激励针对罕见疾病的创新疗法开发。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.